CSIMarket Company Name, Ticker, Industry, else..
 
Replimune Group Inc   (NASDAQ: REPL)
Other Ticker:  
 
 
Price: $8.6200 $0.22 2.619%
Day's High: $9.16 Week Perf: -17.51 %
Day's Low: $ 8.12 30 Day Perf: -28.29 %
Volume (M): 1,436 52 Wk High: $ 17.00
Volume (M$): $ 12,379 52 Wk Avg: $10.39
Open: $8.30 52 Wk Low: $4.92



 Market Capitalization (Millions $) 720
 Shares Outstanding (Millions) 84
 Employees 80
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -228
 Cash Flow (TTM) (Millions $) 75
 Capital Exp. (TTM) (Millions $) 7

Replimune Group Inc
Replimune Group Inc is a biotechnology company that specializes in the development of oncolytic immunotherapies to treat various forms of cancer. They have developed a platform called Immulytic that combines multiple engineering strategies to enhance the selective replication of viruses within tumors, ultimately leading to the destruction of cancer cells. The company aims to provide better treatment options for patients by harnessing the power of the immune system to fight cancer. Replimune Group Inc is based in Woburn, Massachusetts and was founded in 2015.


   Company Address: 500 Unicorn Park Drive Woburn 1801 MA
   Company Phone Number: 222-9600   Stock Exchange / Ticker: NASDAQ REPL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -0.02%    
BEAM   -16.72%    
EXEL        0.54% 
GILD        0.66% 
MRNA   -13.7%    
NVAX   -17.63%    
• View Complete Report
   



Announcement

Replimune Group, Inc. Announces Inducement Grants for Non-Executive Employees Amidst Diminished Revenue

Published Sat, Jan 11 2025 11:22 AM UTC

Replimune Group, Inc. Inducement Grants Overview Replimune Group, Inc. (NASDAQ: REPL), a biotechnology firm engaged in the development of innovative oncolytic immunotherapies, recently issued a press release regarding the grant of inducement equity awards to newly hired non-executive employees. This announcement, made on January 10, 2025, aligns with the Nasdaq Listing Rule ...
Shares

Replimune Secures $125 Million Public Offering to Propel Oncolytic Immunotherapy Advances Amidst Regulatory Triumphs,

Published Mon, Nov 25 2024 12:10 PM UTC

Replimune Moves Forward with $125 Million Public Offering Amid Regulatory Progress and Financial ChallengesWOBURN, Mass., Nov. 25, 2024 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company focused on pioneering oncolytic immunotherapies, has announced a proposed public offering of $125 million in common stock and pre-funded warrants. The offering, ...
Product Service News

Replimune Navigates Regulatory Success and Financial Hurdles in Oncolytic Immunotherapy Landscape,

Published Thu, Nov 21 2024 9:05 PM UTC

Replimune Secures Breakthrough Therapy Designation and Applies for Accelerated FDA Approval Amidst Revenue Challenges In a significant move for the biotechnology industry, Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage company specializing in oncolytic immunotherapies, has announced the submission of a Biologics License Application (BLA) for its investigational thera...
Clinical Study

Replimune Unveils Promising Data from IGNYTE Trial at SITC 2024 RP1 and Nivolumab Show Anti-Tumor Efficacy in A...

Published Sat, Nov 9 2024 6:00 PM UTC

WOBURN, Mass., October 1, 2024 Replimune Group, Inc. (Nasdaq: REPL), an innovative clinical stage biotechnology company committed to developing cutting-edge oncolytic immunotherapies, has made significant strides in the fight against melanoma. This progress was highlighted through a series of presentations aimed at investors and healthcare professionals alike, emphasizing ...
Clinical Study

On November 8, 2024, Replimune Group, Inc. (NASDAQ REPL), a pioneering entity in the field of clinical-stag...

Published Fri, Nov 8 2024 9:01 PM UTC

Replimune s Strategic Inducement Grants Solidify Commitment to Innovative Oncolytic Immunotherapies On November 8, 2024, Replimune Group, Inc. (NASDAQ: REPL), a pioneering entity in the field of clinical-stage biotechnology, made a significant announcement regarding its commitment to bolstering its workforce amidst its ambitious goal of advancing novel oncolytic immunotherap...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com